Resmetirom, a selective thyroid hormone receptor‐β agonist, and the GLP‐1 receptor agonist semaglutide have shown efficacy in reducing inflammation and fibrosis in phase III studies73 and have received approval by the FDA in the USA for the treatment of MASH with fibrosis, but there is no data on HCC incidence. Here, GLP1R is linked to hepatocellular carcinoma.